These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 23597142

  • 1. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
    Graczyk J, Cheung MC, Buckstein R, Chan K.
    Leuk Lymphoma; 2014 Jan; 55(1):56-62. PubMed ID: 23597142
    [Abstract] [Full Text] [Related]

  • 2. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.
    Cheung MC, Prica A, Graczyk J, Buckstein R, Chan KK.
    Leuk Lymphoma; 2016 Aug; 57(8):1865-75. PubMed ID: 26758765
    [Abstract] [Full Text] [Related]

  • 3. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
    Minuk LA, Monkman K, Chin-Yee IH, Lazo-Langner A, Bhagirath V, Chin-Yee BH, Mangel JE.
    Leuk Lymphoma; 2012 Jan; 53(1):57-63. PubMed ID: 21740297
    [Abstract] [Full Text] [Related]

  • 4. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
    Ho P, Sherman P, Grigg A.
    Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.
    Wedgwood A, Younes A.
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S63-6. PubMed ID: 18284718
    [Abstract] [Full Text] [Related]

  • 8. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
    Evens AM, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A, Miyata S, Catsaros K, Augustyniak C, Bennett CL, Tallman MS, Variakojis D, Winter JN, Gordon LI.
    Br J Haematol; 2007 Jun; 137(6):545-52. PubMed ID: 17459049
    [Abstract] [Full Text] [Related]

  • 9. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD.
    Rueda A, Sevilla I, Gumà J, Ribelles N, Miramón J, De Las Nieves MA, Márquez A, Alba E.
    Leuk Lymphoma; 2001 Apr; 41(3-4):353-8. PubMed ID: 11378548
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A.
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [Abstract] [Full Text] [Related]

  • 11. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.
    Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.
    Haematologica; 2019 Feb; 104(2):e65-e67. PubMed ID: 30190343
    [No Abstract] [Full Text] [Related]

  • 12. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P.
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y, Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG).
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [Abstract] [Full Text] [Related]

  • 15. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM.
    Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.
    Schwenkglenks M, Pettengell R, Szucs TD, Culakova E, Lyman GH.
    J Hematol Oncol; 2010 Aug 19; 3():27. PubMed ID: 20723212
    [Abstract] [Full Text] [Related]

  • 18. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.
    Ann Hematol; 2016 Apr 19; 95(5):809-16. PubMed ID: 26878861
    [Abstract] [Full Text] [Related]

  • 19. Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.
    Hay AE, Meyer RM.
    Hematol Oncol Clin North Am; 2014 Feb 19; 28(1):49-63. PubMed ID: 24287067
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.